Healx: AI Pioneer Revolutionizing Rare Disease Treatments

Cambridge-based Healx is transforming drug discovery for rare diseases using advanced AI, machine learning, and biomedical knowledge graphs to repurpose existing compounds. Founded in 2014, the company targets conditions affecting 300 million people worldwide, 90% of which have no approved therapies. With $115-134 million raised, a clinical-stage pipeline targeting Neurofibromatosis, Fragile X Syndrome, and pediatric oncology, and partnerships with Sanofi and SCI Ventures, Healx is expanding into oncology and neuroregeneration. Co-founded by Viagra co-inventor Dr. David Brown, the firm aims to exceed the traditional 5% drug discovery success rate.